drugset / Trial / NCT03250013

Long-term Effects of Medication for ADHD

NCT03250013

Phase 4 Completed 128 enrolled Göteborg University
NaSingle-groupOpen-labelTreatment

Summary

Single-centre open-label prospective study, enrolling 127 children and adolescents aged 6-17 years, who receive medication for ADHD of any subtype (presentation). Long-term results are evaluated with tests of ADHD symptoms (Qb-test), intellectual ability (Wechsler scales; WISC), adaptive functioning (Vineland scale), everyday functioning (Weiss Functional Impairment Scale; WFIRS), and quality of life (Child Health and Illness Profile-Child Edition Scale; CHIP-CE) during 24 months of ADHD treatment.

Timeline

Start
2014-04
Primary completion
2022-01-30
Completion
2022-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphetamine Unknown
Subject Atomoxetine Other / unclassified
Subject Methylphenidate Small molecule